

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

Case Number	Report Entry Date	Gender	Age	Medicine (Onset Time)	Reaction
180679	15/11/2002	Male	3	Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (273 days); Prevenar (Corynebacterium diphtheriae ; Pneumococcal purified capsular polysaccharides) - Suspect (0 days)	Ataxia ; Tremor
182771	11/02/2003	Unknown	4	Menjugate (Corynebacterium diphtheriae ; Neisseria meningitidis group C oligosaccharide) - Suspect (0 days)	Decreased appetite ; Fatigue ; Injection site reaction
184572	2/04/2003	Male	1	Measles Mumps Rubella Vaccine (Measles virus ; Mumps virus ; Rubella virus) - Suspect (21 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (21 days)	Thrombocytopenia
188929	28/07/2003	Male	6	Menjugate (Corynebacterium diphtheriae ; Neisseria meningitidis group C oligosaccharide) - Suspect (0 days)	Erythema ; Injection site reaction ; Swelling
189045	28/07/2003	Male	5	Menjugate (Corynebacterium diphtheriae ; Neisseria meningitidis group C oligosaccharide) - Suspect (0 days)	Cellulitis ; Injection site inflammation
189224	6/08/2003	Unknown	7	Infanrix (Diphtheria toxoid ; Pertactin ; Pertussis filamentous haemagglutinin ; Pertussis toxoid ; Tetanus toxoid) - Suspect (1097 days); Menjugate (Corynebacterium diphtheriae ; Neisseria meningitidis group C oligosaccharide) - Concomitant (1097 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Concomitant (1097 days); Sabin Vaccine (Poliovirus) - Concomitant (1097 days)	Injection site reaction ; Peripheral swelling
190155	3/09/2003	Male	14	ADT Booster (Diphtheria toxoid ; Tetanus toxoid) - Suspect (3 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (3 days)	Cough ; Musculoskeletal pain ; Rhinorrhoea ; Torticollis
190416	11/09/2003	Unknown	1	Infanrix (Diphtheria toxoid ; Pertactin ; Pertussis filamentous haemagglutinin ; Pertussis toxoid ; Tetanus toxoid) - Suspect (0 days); Menjugate (Corynebacterium diphtheriae ; Neisseria meningitidis group C oligosaccharide) - Suspect (0 days)	Diarrhoea ; Oral candidiasis ; Seizure ; Vomiting projectile

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

193164	16/12/2003	Female	15	Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (1 days)	Injection site reaction
193506	23/12/2003	Male	3	Menjugate (Corynebacterium diphtheriae ; Neisseria meningitidis group C oligosaccharide) - Suspect (244 days)	Vaccination failure
195261	11/03/2004	Female	3	Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (-)	Injection site reaction
195378	11/03/2004	Male	3	Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (-)	Anaphylactic reaction ; Presyncope
195602	17/03/2004	Male	16	Menjugate (Corynebacterium diphtheriae ; Neisseria meningitidis group C oligosaccharide) - Suspect (0 days)	Headache
195658	17/03/2004	Male	14	Menjugate (Corynebacterium diphtheriae ; Neisseria meningitidis group C oligosaccharide) - Suspect (0 days)	Headache
199634	4/08/2004	Male	8	Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (3 days)	Headache ; Musculoskeletal stiffness ; Purpura
199709	5/08/2004	Male	12	Hepatitis B Vaccine (Hepatitis B surface antigen recombinant) - Suspect (10 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (10 days)	Dyspnoea ; Empyema ; Mediastinal abscess ; Musculoskeletal stiffness ; Oropharyngeal pain ; Peritonitis ; Pharyngeal abscess ; Pyrexia
201160	23/09/2004	Female	16	Menjugate (Corynebacterium diphtheriae ; Neisseria meningitidis group C oligosaccharide) - Suspect (0 days)	Headache ; Myalgia
203802	23/12/2004	Male	11	Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days)	Headache ; Pruritus ; Syncope
214629	5/01/2006	Female	1	Liquid Pedvaxhib (Haemophilus type B polysaccharide ; Neisseria meningitidis outer membrane protein complex) - Suspect (0 days); Meningitec (Diphtheria CRM197 protein ; Meningococcal polysaccharide group C) - Suspect (0 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days)	Unevaluable event
222950	7/11/2006	Male	1	Meningitec (Diphtheria CRM197 protein ; Meningococcal polysaccharide group C) - Suspect (0 days); Pedvaxhib (Haemophilus	Flushing ; Rash erythematous ; Urticaria

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

				type B polysaccharide ; Neisseria meningitidis outer membrane protein complex) - Suspect (0 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days)	
225961	20/02/2007	Male	45	Boostrix-IPV (Diphtheria toxoid ; Pertactin ; Pertussis filamentous haemagglutinin ; Pertussis toxoid ; Poliovirus ; Tetanus toxoid) - Suspect (2 days); Dukoral (Vibrio cholerae) - Suspect (9 days); Fluvax (Influenza virus haemagglutinin) - Suspect (9 days); Hepatitis B Vaccine (Hepatitis B surface antigen recombinant) - Suspect (2 days); Menomune (Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y) - Suspect (9 days); Merieux Inactivated Rabies Vaccine (Rabies virus) - Suspect (9 days); Pneumovax (Pneumococcal purified capsular polysaccharides) - Suspect (2 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (2 days); Stamaril (Yellow fever virus) - Suspect (2 days); Vivaxim (Hepatitis a virus antigen ; Salmonella typhi Vi polysaccharide) - Suspect (2 days)	Rash
234529	17/10/2007	Male	1	Menjugate (Corynebacterium diphtheriae ; Neisseria meningitidis group C oligosaccharide) - Suspect (10 days); Pedvaxhib (Haemophilus type B polysaccharide ; Neisseria meningitidis outer membrane protein complex) - Suspect (10 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (10 days); VAQTa Hepatitis A Vaccine Inactivated (Hepatitis a virus antigen) - Suspect (10 days)	Generalised oedema ; Rash generalised ; Tongue oedema
245756	23/10/2008	Female	4	Liquid Pedvaxhib (Haemophilus type B polysaccharide ; Neisseria meningitidis outer membrane protein complex) - Suspect (6 days); Meningitec (Diphtheria CRM197 protein ; Meningococcal polysaccharide group C) - Suspect (6 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (6 days)	Angioedema ; Pyrexia ; Rash
261400	23/12/2009	Female	5	Comvax (Haemophilus influenza type B polyribose ribitol phosphate ;	Cyanosis ; Hypotension ; Hypotonia

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

				Hepatitis B surface antigen recombinant ; Neisseria meningitidis outer membrane protein complex) - Suspect (0 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days)	
262555	8/02/2010	Female	1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (7 days); M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (7 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (7 days); Panvax H1N1 influenza vaccine Junior (Influenza virus haemagglutinin) - Suspect (7 days)	Cough ; Eye discharge ; Pyrexia ; Rash
265070	14/04/2010	Female	47	Boostrix (Diphtheria toxoid ; Pertactin ; Pertussis filamentous haemagglutinin ; Pertussis toxoid ; Tetanus toxoid) - Suspect (0 days); Meningitec (Diphtheria CRM197 protein ; Meningococcal polysaccharide group C) - Concomitant (0 days); Panvax H1N1 influenza vaccine (Influenza virus haemagglutinin) - Suspect (0 days); Typherix (Salmonella typhi Vi polysaccharide) - Concomitant (0 days)	Accidental overdose ; Eye discharge ; Eye pain ; Headache ; Influenza like illness ; Injection site pain ; Injection site reaction ; Lethargy ; Oropharyngeal pain ; Periorbital oedema ; Somnolence ; Swelling face
266557	4/05/2010	Female	1	Fluvax (Influenza virus haemagglutinin) - Suspect (0 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days)	Pyrexia
267497	17/05/2010	Male	1	Fluvax (Influenza virus haemagglutinin) - Suspect (0 days); Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (0 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days); Trade Name Not Specified (Product not Coded) - Suspect (0 days)	Febrile convulsion
269658	23/06/2010	Female	1	Fluvax (Influenza virus haemagglutinin) - Suspect (0 days); Hiberix	Dyspnoea ; Pyrexia

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

				(Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (0 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days)	
269916	28/06/2010	Male	1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (1 days); Measles Mumps Rubella Vaccine (Measles virus ; Mumps virus ; Rubella virus) - Suspect (1 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (1 days)	Pyrexia ; Urticaria
270425	7/07/2010	Male	1	Comvax (Haemophilus influenza type B polyribose ribitol phosphate ; Hepatitis B surface antigen recombinant ; Neisseria meningitidis outer membrane protein complex) - Concomitant (0 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days)	Injection site reaction ; Swelling face
272815	31/08/2010	Female	<1	Infanrix HEXA (Diphtheria toxoid ; Haemophilus influenza type B polyribose ribitol phosphate ; Hepatitis B surface antigen recombinant ; Pertactin ; Pertussis filamentous haemagglutinin ; Pertussis toxoid ; Poliovirus ; Tetanus toxoid) - Concomitant (-); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (-); Prevenar (Corynebacterium diphtheriae ; Pneumococcal purified capsular polysaccharides) - Concomitant (-); Rotateq (Rotavirus G1 human-bovine reassortant ; Rotavirus G2 human-bovine reassortant ; Rotavirus G3 human-bovine reassortant ; Rotavirus G4 human-bovine reassortant ; Rotavirus P1 [8] human-bovine reassortant) - Concomitant (-)	Vaccination error
285520	6/07/2011	Female	<1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (0 days); Neisvac-C (aluminium hydroxide	Hypophagia ; Irritability ; Lethargy ; Pyrexia

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

				hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days); Prevenar (Corynebacterium diphtheriae ; Pneumococcal purified capsular polysaccharides) - Suspect (0 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days); Trade Name Not Specified (Product not Coded) - Suspect (0 days)	
289925	5/10/2011	Male	1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (0 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days)	Pruritus ; Rash erythematous ; Urticaria
291383	4/11/2011	Female	1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (6 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (6 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (6 days)	Seizure
292368	25/11/2011	Male	1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (14 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (14 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (14 days)	Febrile convulsion
294667	17/01/2012	Male	1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (0 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days); Prevenar 13 (Pneumococcal purified capsular polysaccharides) - Suspect (0 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days)	Crying ; Hypotonic-hyporesponsive episode
308664	19/10/2012	Male	1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (0 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) -	Injection site nodule ; Injection site reaction

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

Suspect (0 days)					
310822	4/12/2012	Male	1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (0 days); Meningitec (Diphtheria CRM197 protein ; Meningococcal polysaccharide group C) - Suspect (0 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days)	Urticaria
311781	24/12/2012	Female	1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (2 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (2 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (2 days)	Hypotonic-hyporesponsive episode ; Pyrexia
315929	20/03/2013	Male	1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (3 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (3 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (3 days)	Rash generalised
316162	25/03/2013	Male	1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (1 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (1 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (1 days)	Decreased appetite ; Rash macular ; Rhinorrhoea
317452	10/04/2013	Male	1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (0 days); Meningitec (Diphtheria CRM197 protein ; Meningococcal polysaccharide group C) - Suspect (0 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days)	Meningitis bacterial ; Seizure
318917	2/05/2013	Female	1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (2 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (2 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (2 days)	Rash generalised

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

322260	27/06/2013	Female	2	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (14 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (14 days); Prevenar 13 (Pneumococcal purified capsular polysaccharides) - Suspect (14 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (14 days)	Cardiac arrest ; Pharyngitis ; Pyrexia
323141	15/07/2013	Female	23	Menveo (Diphtheria CRM197 protein ; Meningococcal oligosaccharide group A ; Meningococcal oligosaccharide group C ; Meningococcal oligosaccharide group W135 ; Meningococcal oligosaccharide group Y) - Concomitant (35 days); Metoprolol (Metoprolol tartrate) - Concomitant (90 days); Trade Name Not Specified (Darbepoetin alfa) - Concomitant (204 days); Trade Name Not Specified (Eculizumab) - Suspect (61 days); Trade Name Not Specified (Gliclazide) - Concomitant (204 days); Trade Name Not Specified (Hydralazine hydrochloride) - Concomitant (476 days); Trade Name Not Specified (Lercanidipine hydrochloride) - Concomitant (462 days); Trade Name Not Specified (Omeprazole) - Concomitant (344 days); Trade Name Not Specified (Prednisolone) - Concomitant (137 days); Trade Name Not Specified (Product not Coded) - Concomitant (504 days); Trade Name Not Specified (Tacrolimus) - Concomitant (504 days); Trade Name Not Specified (amphotericin B (amphotericin)) - Concomitant (170 days); Trade Name Not Specified (colecalfiferol) - Concomitant (503 days); Trade Name Not Specified (magnesium aspartate) - Concomitant (200 days); Trade Name Not Specified (sodium bicarbonate) - Concomitant (170 days); Trimethoprim-sulfamethoxazole (Sulfamethoxazole ; Trimethoprim) - Concomitant (503 days)	Anaemia
325707	26/08/2013	Female	1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (1 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) -	Pyrexia ; Rash maculo-papular ; Urticaria

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

				Suspect (1 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (1 days)	
326007	30/08/2013	Female	1	Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days)	Urticaria
326706	11/09/2013	Male	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (17 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (17 days)	Exanthema subitum ; Febrile convulsion ; Lethargy ; Pyrexia ; Rash macular ; Vomiting
328346	9/10/2013	Male	5	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Concomitant (0 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days); Quadracel (Diphtheria toxoid ; Pertactin ; Pertussis filamentous haemagglutinin ; Pertussis fimbriae 2 + 3 ; Pertussis toxoid ; Poliovirus ; Tetanus toxoid) - Suspect (0 days)	Drug administration error
328356	9/10/2013	Female	1	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (-); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (-); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (-)	Urinary tract infection
330378	7/11/2013	Male	1	Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (2 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (2 days)	Rash
331740	27/11/2013	Male	1	Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days)	Wrong drug administered
332774	19/12/2013	Female	22	Menactra (Diphtheria toxoid ; Meningococcal polysaccharide group A ;	Rash pruritic

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

				Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y) - Suspect (0 days); Stamaril (Yellow fever virus) - Suspect (5 days)	
332897	23/12/2013	Female	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Concomitant (-); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days)	No adverse event ; Product packaging issue ; Wrong technique in product usage process
332912	23/12/2013	Male	4	Fluarix (Influenza virus haemagglutinin) - Suspect (3 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (3 days)	No adverse event
335474	25/02/2014	Female	1	Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (1 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (1 days)	Otitis media ; Pharyngitis
335847	4/03/2014	Female	1	Fluarix (Influenza virus haemagglutinin) - Suspect (1 days); Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (1 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (1 days)	Seizure
338234	9/04/2014	Female	43	Hiberix (Haemophilus influenza type B polyribose ribitol phosphate ; Tetanus toxoid) - Suspect (1 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (1 days); Pneumovax 23 (Pneumococcal purified capsular polysaccharides) - Suspect (1 days); Vaxigrip (Influenza virus haemagglutinin) - Suspect (1 days)	Pain in extremity ; Pyrexia ; Rash erythematous ; Vomiting
338406	10/04/2014	Male	3	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding	Eye swelling ; Injection site swelling

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

				Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (-); Influenza Vaccine (Influenza virus haemagglutinin) - Suspect (-)	
338907	22/04/2014	Male	1	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (0 days)	Pyrexia ; Urine output increased
339636	2/05/2014	Male	9	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (0 days)	Swelling
339664	2/05/2014	Female	<1	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (2 days)	Infection ; No adverse event
349999	11/11/2014	Male	1	Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (1 days); Priorix-Tetra (live varicella vaccine ; Measles virus ; Mumps virus ; Rubella virus) - Suspect (1 days)	Crying ; Nightmare ; Stubbornness
353949	4/02/2015	Female	8	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (1 days)	Injection site reaction ; Pain in extremity ; Pyrexia ; Urticaria ; Urticaria
354764	19/02/2015	Male	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days); Menitorix (Haemophilus influenza type B polyribose ribitol	Rash generalised

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

				phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days)	
355351	2/03/2015	Male	1	Measles Mumps Rubella Vaccine (Measles virus ; Mumps virus ; Rubella virus) - Suspect (1 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (1 days)	Diarrhoea ; Haematochezia ; Injection site reaction ; Lethargy ; Vomiting
357639	15/04/2015	Female	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (7 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (7 days)	Concomitant disease progression ; Lethargy ; Pyrexia ; Seizure ; Vomiting
357925	20/04/2015	Female	1	Measles Mumps Rubella Vaccine (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days)	Injection site erythema ; Pruritus
359345	13/05/2015	Female	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (8 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (8 days)	Pyrexia ; Rash
359824	20/05/2015	Male	1	Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (6 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (6 days)	Decreased appetite ; Pyrexia ; Rash generalised ; Somnolence
366337	26/08/2015	Female	1	Measles Mumps Rubella Vaccine (Measles virus ; Mumps virus ; Rubella virus) - Suspect (1 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (1 days)	Angioedema ; Mouth ulceration ; Pyrexia ; Vomiting
373254	16/12/2015	Female	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) -	Rash

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

Suspect (0 days)					
374970	27/01/2016	Male	<1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days)	Injection site erythema ; Irritability postvaccinal ; Rash
375757	12/02/2016	Male	3	Infanrix HEXA (Diphtheria toxoid ; Haemophilus influenza type B polyribose ribitol phosphate ; Hepatitis B surface antigen recombinant ; Pertactin ; Pertussis filamentous haemagglutinin ; Pertussis toxoid ; Poliovirus ; Tetanus toxoid) - Suspect (0 days); M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days); Prevenar 13 (Pneumococcal purified capsular polysaccharides) - Suspect (0 days)	Body temperature increased ; Flushing ; Rash ; Syncope
377370	15/03/2016	Female	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Concomitant (0 days)	Injection site reaction
387385	4/05/2016	Male	10	Boostrix (Diphtheria toxoid ; Pertactin ; Pertussis filamentous haemagglutinin ; Pertussis toxoid ; Tetanus toxoid) - Suspect (0 days); H-B-Vax II Vaccine Paediatric (Hepatitis B surface antigen recombinant) - Suspect (0 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days); Proquad (live varicella vaccine ; Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days)	Pruritus ; Rash
390087	15/06/2016	Male	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days)	Urticaria
391385	8/07/2016	Male	12	H-B-Vax II Vaccine Paediatric (Hepatitis B surface antigen recombinant)	Febrile convulsion ; Viral infection

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

				- Suspect (1 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (1 days)	
391794	15/07/2016	Female	1	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (1 days)	Hypotonic-hyporesponsive episode ; Pyrexia ; Vomiting
392564	1/08/2016	Female	44	Fluarix Tetra Vaccine (Influenza virus haemagglutinin) - Suspect (1 days); Menactra (Diphtheria toxoid ; Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y) - Suspect (1 days); Merieux Inactivated Rabies Vaccine (Rabies virus) - Suspect (1 days)	Facial paralysis
393277	11/08/2016	Female	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days)	Injection site reaction
395007	12/09/2016	Female	50	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (0 days); Crestor (Rosuvastatin calcium) - Concomitant (-); Duromine (phentermine) - Concomitant (-); Fluvax (Influenza virus haemagglutinin) - Concomitant (-); Hepatitis B Vaccine (Hepatitis B surface antigen recombinant) - Concomitant (-); Prevenar 13 (Pneumococcal purified capsular polysaccharides) - Concomitant (-); Vivaxim (Hepatitis a virus antigen ; Salmonella typhi Vi polysaccharide) - Concomitant (-)	Posterior reversible encephalopathy syndrome

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

396720	11/10/2016	Male	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days)	Wheezing
397236	20/10/2016	Female	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (3 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (3 days)	Rash
398475	4/11/2016	Female	11	Menactra (Diphtheria toxoid ; Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y) - Suspect (-)	Beta haemolytic streptococcal infection ; Necrotising fasciitis ; Toxic shock syndrome
400137	5/12/2016	Female	4	Menveo (Diphtheria CRM197 protein ; Meningococcal oligosaccharide group A ; Meningococcal oligosaccharide group C ; Meningococcal oligosaccharide group W135 ; Meningococcal oligosaccharide group Y) - Suspect (0 days); Pneumovax 23 (Pneumococcal purified capsular polysaccharides) - Suspect (0 days)	Extensive swelling of vaccinated limb ; Pyrexia
403538	13/02/2017	Male	1	Infanrix HEXA (Diphtheria toxoid ; Haemophilus influenza type B polyribose ribitol phosphate ; Hepatitis B surface antigen recombinant ; Pertactin ; Pertussis filamentous haemagglutinin ; Pertussis toxoid ; Poliovirus ; Tetanus toxoid) - Suspect (0 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Concomitant (0 days); Prevenar 13 (Pneumococcal purified capsular polysaccharides) - Concomitant (159 days)	Injection site infection ; Injection site vesicles
404394	28/02/2017	Female	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (3 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (3 days)	Rash
408619	9/05/2017	Female	66	Menveo (Diphtheria CRM197 protein ; Meningococcal oligosaccharide group A ; Meningococcal oligosaccharide group C ; Meningococcal	Death

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

				oligosaccharide group W135 ; Meningococcal oligosaccharide group Y) - Suspect (4 days)	
413884	12/07/2017	Male	1	FluQuadri Junior (Influenza virus haemagglutinin) - Suspect (0 days); M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days)	Death
414556	21/07/2017	Male	1	FluQuadri Junior (Influenza virus haemagglutinin) - Suspect (-); M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (-); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (-)	Death
414566	21/07/2017	Female	16	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (0 days)	Periarthritis
414729	25/07/2017	Male	34	Meningitec (Diphtheria CRM197 protein ; Meningococcal polysaccharide group C) - Suspect (4565 days)	Vaccination failure
414755	25/07/2017	Female	15	Menactra (Diphtheria toxoid ; Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y) - Suspect (1 days)	Injection site reaction
415058	31/07/2017	Male	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (23 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (23 days)	Pruritus ; Rash generalised
415063	31/07/2017	Male	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (21 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) -	Urticaria

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

Suspect (21 days)						
415200	1/08/2017	Male	7	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (-); Menactra (Diphtheria toxoid ; Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y) - Suspect (-); Trade Name Not Specified (Amitriptyline) - Concomitant (-); Trade Name Not Specified (Gabapentin) - Concomitant (-)	Anastomotic ulcer ; Rectal haemorrhage	
415322	2/08/2017	Female	15	Menactra (Diphtheria toxoid ; Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y) - Suspect (0 days)	Anaphylactic reaction ; Dysphagia ; Dysphonia ; Dyspnoea ; Erythema ; Eye pruritus ; Eye swelling ; Rash erythematous ; Tachycardia ; Wheezing	
416844	24/08/2017	Female	15	Menactra (Diphtheria toxoid ; Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y) - Suspect (0 days)	Nausea ; Urticaria	
417665	7/09/2017	Female	1	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (1 days)	Injection site reaction	
417808	11/09/2017	Female	15	Menactra (Diphtheria toxoid ; Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y) - Suspect (2 days)	Encephalitis	

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

418110	14/09/2017	Male	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days)	Anaphylactic reaction
418236	15/09/2017	Male	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days)	Anaphylactic reaction ; Hypotonia ; Somnolence ; Swelling face ; Urticaria
418481	20/09/2017	Female	15	Menactra (Diphtheria toxoid ; Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y) - Suspect (-)	Abnormal behaviour ; Abnormal behaviour ; Aggression ; Aggression ; Encephalitis autoimmune ; Encephalitis autoimmune ; Hallucinations, mixed ; Hallucinations, mixed ; Psychiatric symptom ; Psychiatric symptom ; Seizure ; Seizure
419420	5/10/2017	Female	1	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (0 days)	Type 1 diabetes mellitus
419598	10/10/2017	Male	<1	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (3 days)	Urticaria
419921	16/10/2017	Female	16	Menactra (Diphtheria toxoid ; Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y) - Suspect (1	Injection site reaction

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

				days)		
420120	18/10/2017	Male	1	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (0 days)		Injection site nodule ; Throat irritation
421081	1/11/2017	Male	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (1 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (306 days)		Generalised tonic-clonic seizure ; Pyrexia ; Vomiting
422536	22/11/2017	Male	1	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (234 days)		Injection site mass
423500	7/12/2017	Male	46	Menveo (Diphtheria CRM197 protein ; Meningococcal oligosaccharide group A ; Meningococcal oligosaccharide group C ; Meningococcal oligosaccharide group W135 ; Meningococcal oligosaccharide group Y) - Suspect (0 days)		Vaccination error
424840	3/01/2018	Female	3	Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (-)		Nonspecific reaction
425371	11/01/2018	Male	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days)		Anaphylactic reaction
425762	19/01/2018	Female	7	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer		Urticaria

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

				membrane vesicles) - Suspect (-)	
426032	24/01/2018	Female	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (14 days); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Concomitant (14 days)	Encephalitis
426294	30/01/2018	Female	5	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (0 days)	Injection site reaction ; Limb immobilisation
427598	19/02/2018	Female	9	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (2 days); Menveo (Diphtheria CRM197 protein ; Meningococcal oligosaccharide group A ; Meningococcal oligosaccharide group C ; Meningococcal oligosaccharide group W135 ; Meningococcal oligosaccharide group Y) - Suspect (2 days)	Injection site reaction ; Paraesthesia
427602	19/02/2018	Male	4	Nimenrix (Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y ; Tetanus toxoid) - Suspect (1 days)	Urticaria
427618	19/02/2018	Female	1	Menveo (Diphtheria CRM197 protein ; Meningococcal oligosaccharide group A ; Meningococcal oligosaccharide group C ; Meningococcal oligosaccharide group W135 ; Meningococcal oligosaccharide group Y) - Concomitant (7 days); Prevenar 13 (Pneumococcal purified capsular polysaccharides) - Concomitant (7 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (7 days)	Morbillivirus test positive
427645	19/02/2018	Female	9	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein	Injection site reaction ; Paraesthesia

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

				fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (2 days); Menveo (Diphtheria CRM197 protein ; Meningococcal oligosaccharide group A ; Meningococcal oligosaccharide group C ; Meningococcal oligosaccharide group W135 ; Meningococcal oligosaccharide group Y) - Suspect (2 days)	
428251	27/02/2018	Female	49	Menactra (Diphtheria toxoid ; Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y) - Suspect (-)	Arthralgia ; Chest pain ; Guillain-Barre syndrome ; Mobility decreased ; Muscle spasms ; Muscular weakness ; Muscular weakness ; Musculoskeletal pain ; Myelitis transverse
429034	13/03/2018	Male	3	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (0 days); Menveo (Diphtheria CRM197 protein ; Meningococcal oligosaccharide group A ; Meningococcal oligosaccharide group C ; Meningococcal oligosaccharide group W135 ; Meningococcal oligosaccharide group Y) - Suspect (0 days)	Eye swelling ; Lethargy ; Pallor ; Rash
434233	24/05/2018	Female	15	FluQuadri Vaccine (Influenza virus haemagglutinin) - Suspect (0 days); Menactra (Diphtheria toxoid ; Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y) - Suspect (0 days)	Dizziness ; Myalgia ; Pain in extremity ; Rash
439309	1/08/2018	Female	13	Trumenba (Neisseria meningitidis serogroup B recombinant lipidated-factor H binding protein subfamily A ; Neisseria meningitidis serogroup B recombinant lipidated- factor H binding protein subfamily B) -	Bradypnea ; Fatigue ; Headache ; Hypotension ; Loss of personal independence in daily activities ;

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

				Suspect (-)	Menstruation irregular ; Nausea ; Premenstrual syndrome
444382	19/09/2018	Female	12	Menactra (Diphtheria toxoid ; Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y) - Suspect (0 days)	Erythema ; Pruritus
448903	26/10/2018	Female	1	Infanrix (Diphtheria toxoid ; Pertactin ; Pertussis filamentous haemagglutinin ; Pertussis toxoid ; Tetanus toxoid) - Suspect (0 days); Nimenrix (Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y ; Tetanus toxoid) - Suspect (0 days); Proquad (live varicella vaccine ; Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days)	Pyrexia ; Vomiting
449562	2/11/2018	Female	1	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (5 days); Nimenrix (Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y ; Tetanus toxoid) - Suspect (5 days)	Measles
452997	12/12/2018	Unknown	2	M-M-R II (Measles virus ; Mumps virus ; Rubella virus) - Suspect (-); Menitorix (Haemophilus influenza type B polyribose ribitol phosphate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (-)	Febrile convulsion
456690	8/02/2019	Male	2	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (1 days)	Nonspecific reaction
456831	11/02/2019	Male	<1	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding	Rash

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

				Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (-)	
459850	18/03/2019	Male	<1	Bexsero (Neisseria meningitidis Group B Factor H Binding Protein fusion protein ; Neisseria meningitidis Group B Neisseria Adhesin A protein ; Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein ; Neisseria meningitidis serogroup B outer membrane vesicles) - Suspect (-); Infanrix HEXA (Diphtheria toxoid ; Haemophilus influenza type B polyribose ribitol phosphate ; Hepatitis B surface antigen recombinant ; Pertactin ; Pertussis filamentous haemagglutinin ; Pertussis toxoid ; Poliovirus ; Tetanus toxoid) - Concomitant (-); Nurofen (Ibuprofen) - Concomitant (-); Panadol (Paracetamol) - Suspect (1 days)	Blood glucose decreased ; Diarrhoea ; Faeces discoloured ; Fluid intake reduced ; Giardiasis ; Malaise ; Off label use ; Vomiting
467082	31/05/2019	Unknown	-	Nimenrix (Meningococcal polysaccharide group A ; Meningococcal polysaccharide group C ; Meningococcal polysaccharide group W135 ; Meningococcal polysaccharide Group Y ; Tetanus toxoid) - Suspect (-)	Product quality issue
467088	31/05/2019	Female	<1	Influenza Vaccine (Influenza virus haemagglutinin) - Suspect (0 days); Neisvac-C (aluminium hydroxide hydrate ; Meningococcal polysaccharide group C ; Tetanus toxoid) - Suspect (0 days); Priorix (Measles virus ; Mumps virus ; Rubella virus) - Suspect (0 days)	Aphasia ; Bedridden ; Blood test abnormal ; Bone marrow failure ; Brain injury ; Cerebral ischaemia ; Computerised tomogram abnormal ; Crying ; Cyanosis ; Device dependence ; Diarrhoea ; Disability ; Dyspnoea ; Dystonia ; Epilepsy ; Febrile convulsion ; Feeding disorder ; Feeling abnormal ; Gait inability ; Heart rate increased ; Hepatic failure ; Human rhinovirus test positive ; Hypoglycaemia ; Hypokinesia ; Hypotonia ; Hypoxia ; Inability to crawl ; Infection ; Injury ; Lethargy ;

The information provided in the following table is from reports included in the Adverse Event Management System (TGA's internal adverse event database) but not included in the Database of Adverse Event Notifications (DAEN). The reports that do not appear in the DAEN may have insufficient information and/or no reasonable temporal association and/or the relationship between the medicine/vaccine and the adverse event appears to not be related as judged by a health professional and/or the report may have been received by the TGA within the last 90 days and/or the report may be a duplicate of a case included in the DAEN and/or was reported as part of a clinical trial or individual patient access.

Listless ; Liver injury ; Loss of personal independence in daily activities ; Malaise ; Metabolic acidosis ; Moaning ; Multiple organ dysfunction syndrome ; Muscle twitching ; Muscular weakness ; Nervous system disorder ; Pain ; Pallor ; Partial seizures ; Product administered to patient of inappropriate age ; Pyrexia ; Quadriplegia ; Quality of life decreased ; Renal failure ; Respiratory disorder ; Respiratory syncytial virus infection ; Restlessness ; Screaming ; Seizure ; Strabismus ; Tremor ; Unrespons